# An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

> **NCT00094770** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1172 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** sitagliptin (MK0431)
- **DRUG:** Comparator: glipizide

## Key facts

- **NCT ID:** NCT00094770
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2006-05
- **Final completion:** 2007-05
- **Target enrollment:** 1172 (ACTUAL)
- **Last updated:** 2016-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094770, "An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00094770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*